See more : Property Solutions Acquisition Corp. II (PSAGW) Income Statement Analysis – Financial Results
Complete financial analysis of BioArctic AB (publ) (BRCTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioArctic AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Hanwha Corporation (000885.KS) Income Statement Analysis – Financial Results
- Global Data Centre Group (GDC.AX) Income Statement Analysis – Financial Results
- United Rentals, Inc. (0LIY.L) Income Statement Analysis – Financial Results
- SES S.A. (SESG.PA) Income Statement Analysis – Financial Results
- Pendragon PLC (PDGNF) Income Statement Analysis – Financial Results
BioArctic AB (publ) (BRCTF)
About BioArctic AB (publ)
BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 616.00M | 228.29M | 23.15M | 62.35M | 281.77M | 713.97M | 140.71M | 105.61M | 41.57M |
| Cost of Revenue | 89.63M | 74.33M | 55.07M | 50.24M | 72.42M | 145.36M | 63.64M | 238.00K | 0.00 |
| Gross Profit | 526.37M | 153.97M | -31.92M | 12.11M | 209.35M | 568.61M | 77.07M | 105.38M | 41.57M |
| Gross Profit Ratio | 85.45% | 67.44% | -137.91% | 19.42% | 74.30% | 79.64% | 54.77% | 99.77% | 100.00% |
| Research & Development | 0.00 | 7.10M | 6.06M | 6.12M | 7.74M | 16.40M | 101.58M | 53.67M | 38.24M |
| General & Administrative | 0.00 | 0.00 | 24.85M | 23.37M | 31.17M | 31.95M | 31.52M | 14.54M | 4.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.40M | 1.37M | 1.45M |
| SG&A | 251.25M | 148.67M | 24.85M | 23.37M | 31.17M | 31.95M | 32.92M | 15.91M | 6.01M |
| Other Expenses | 22.48M | 0.00 | 0.00 | 0.00 | 0.00 | 7.00K | 678.00K | 2.08M | 524.00K |
| Operating Expenses | 273.73M | 161.90M | 107.93M | 94.42M | 98.26M | 82.79M | 53.72M | 44.77M | 37.27M |
| Cost & Expenses | 363.36M | 236.23M | 163.00M | 144.67M | 170.68M | 228.14M | 117.36M | 45.01M | 37.27M |
| Interest Income | 34.23M | 2.54M | 0.00 | 7.00K | 253.00K | 40.00K | 65.00K | 8.00K | 232.00K |
| Interest Expense | 379.00K | 559.00K | 838.00K | 984.00K | 1.19M | 1.37M | 647.00K | 5.00K | 8.00K |
| Depreciation & Amortization | 18.43M | 14.63M | 13.11M | 11.01M | 9.20M | 2.06M | 1.99M | 1.56M | 1.54M |
| EBITDA | 295.24M | 4.03M | -126.57M | -74.69M | 123.37M | 487.89M | 26.02M | 64.24M | 6.36M |
| EBITDA Ratio | 47.93% | 1.76% | -546.78% | -119.47% | 43.78% | 69.05% | 15.42% | 71.67% | 15.26% |
| Operating Income | 252.64M | -17.44M | -139.72M | -85.01M | 112.54M | 488.79M | 19.29M | 74.63M | 4.84M |
| Operating Income Ratio | 41.01% | -7.64% | -603.66% | -136.35% | 39.94% | 68.46% | 13.71% | 70.66% | 11.65% |
| Total Other Income/Expenses | 23.85M | 6.17M | -788.00K | -1.68M | 437.00K | 799.00K | 397.00K | -495.00K | -53.00K |
| Income Before Tax | 276.49M | -11.17M | -140.51M | -86.69M | 112.98M | 489.59M | 19.69M | 74.14M | 4.79M |
| Income Before Tax Ratio | 44.88% | -4.89% | -607.06% | -139.05% | 40.09% | 68.57% | 13.99% | 70.20% | 11.52% |
| Income Tax Expense | 47.24M | 11.00K | -20.72M | -18.17M | 24.51M | 107.99M | 4.53M | 16.56M | 1.08M |
| Net Income | 229.25M | -11.18M | -119.79M | -68.52M | 88.47M | 381.60M | 15.16M | 57.58M | 3.71M |
| Net Income Ratio | 37.22% | -4.90% | -517.54% | -109.90% | 31.40% | 53.45% | 10.77% | 54.52% | 8.92% |
| EPS | 2.59 | -0.13 | -1.36 | -0.78 | 1.00 | 4.33 | 0.22 | 0.65 | 0.04 |
| EPS Diluted | 2.59 | -0.13 | -1.36 | -0.78 | 1.00 | 4.33 | 0.22 | 0.65 | 0.04 |
| Weighted Avg Shares Out | 88.51M | 88.07M | 88.06M | 88.06M | 88.06M | 88.06M | 88.06M | 88.06M | 88.06M |
| Weighted Avg Shares Out (Dil) | 88.49M | 88.07M | 88.06M | 88.06M | 88.06M | 88.06M | 88.06M | 88.06M | 88.06M |
Leqembi® approved in Mexico
Leqembi® launched in South Korea
CHMP issues positive recommendation for approval of lecanemab in the EU
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
BioArctic AB: The David Against Goliath Of Solving Alzheimer's Disease
Eisai will request reconsideration of initial decision for lecanemab in Australia
Leqembi approved for the treatment of Alzheimer's disease in the United Arab Emirates
Leqembi revenue more than doubled - totaled JPY 6.3 billion in the second quarter 2024
Eisai will seek re-examination of CHMP opinion för lecanemab
Leqembi approved for the treatment of Alzheimer's disease in Hong Kong
Source: https://incomestatements.info
Category: Stock Reports